PF-Atlas › Clinical Trials › NCT05870956

Burden of Nintedanib Non-adherence Among Idiopathic Pulmonary Fibrosis Patients

Nintedanib · Not specified

Registry ID
NCT05870956
Phase
Not specified
Status
Completed
Drug / intervention
Nintedanib
Sponsor
Boehringer Ingelheim
Start
2023-05-16
Enrollment
1798
Locations
1

About this trial

This study has two objectives: 1. To assess the association between nintedanib adherence trajectory group (as measured from a Group-based Trajectory Modelling (GBTM)) and health care resource use, with a focus on inpatient hospitalization, among patients with Idiopathic Pulmonary Fibrosis (IPF). 2. To assess the association between a patient's nintedanib adherence trajectory group (as measured from a GBTM) and their medical costs among patients with IPF.

View NCT05870956 on ClinicalTrials.gov →

Explore related

All Nintedanib trialsAll IPF trials

Related trials

nintedanib — NCT02606877Nintedanib — NCT02598193Nintedanib — NCT02579603Nintedanib — NCT02597933Nintedanib — NCT02999178Nintedanib — NCT02607722
Medical disclaimer. This page summarizes public trial data for NCT05870956 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.